Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, BBOT, EYPT, EWTX, ERAS, and represent 37.59% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: ERAS (+$94M), DNTH (+$80M), DMRA (+$40M), TNGX (+$30M), AgomAb Therapeutics NV (+$26M), OLMA (+$25M), MAZE (+$22M), ROIV (+$21M), ANL (+$20M), TERN (+$16M).
- Started 17 new stock positions in DMRA, TERN, GLUE, DNTH, SNSE, AgomAb Therapeutics NV, ZURA, MAZE, GPCR, ROIV. ARWR, ERAS, ANL, RLYB, Helix Acquisition Corp Iii, TNGX, CNTX.
- Reduced shares in these 10 stocks: QQQ (-$154M), IWM (-$123M), , ABVX (-$66M), ENGN (-$36M), BBIO (-$26M), PRAX (-$21M), GHRS (-$17M), INSM (-$14M), CNTA (-$11M).
- Sold out of its positions in ENGN, QQQ, IWM, JANX, XBI, GHRS.
- Cormorant Asset Management was a net seller of stock by $-146M.
- Cormorant Asset Management has $2.0B in assets under management (AUM), dropping by -7.93%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 46 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 14.3 | $285M | -6% | 886k | 322.19 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 8.0 | $160M | 18M | 8.95 |
|
|
| Eyepoint Com New (EYPT) | 5.4 | $107M | 8.3M | 12.89 |
|
|
| Edgewise Therapeutics (EWTX) | 5.2 | $103M | 3.3M | 31.50 |
|
|
| Erasca (ERAS) | 4.7 | $94M | NEW | 5.8M | 16.18 |
|
| Rapport Therapeutics (RAPP) | 4.6 | $93M | -2% | 3.0M | 31.29 |
|
| Alumis (ALMS) | 4.4 | $87M | +8% | 3.9M | 22.03 |
|
| Abivax Sa Sponsored Ads (ABVX) | 4.3 | $85M | -43% | 760k | 111.35 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 4.2 | $84M | +2% | 4.5M | 18.64 |
|
| Dianthus Therapeutics (DNTH) | 4.0 | $80M | NEW | 950k | 83.92 |
|
| Bright Minds Biosciences Com New (DRUG) | 3.9 | $77M | 1.1M | 72.97 |
|
|
| Olema Pharmaceuticals (OLMA) | 3.3 | $66M | +60% | 4.4M | 14.91 |
|
| Bridgebio Pharma (BBIO) | 3.2 | $63M | -29% | 850k | 74.26 |
|
| Bioage Labs (BIOA) | 2.5 | $51M | +41% | 2.9M | 17.49 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.1 | $42M | -20% | 1.1M | 39.72 |
|
| Damora Therapeutics Com New (DMRA) | 2.0 | $40M | NEW | 1.5M | 25.90 |
|
| Mbx Biosciences (MBX) | 1.7 | $33M | 1.1M | 29.85 |
|
|
| Insmed Com Par $.01 (INSM) | 1.6 | $31M | -30% | 190k | 163.52 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.5 | $30M | -5% | 950k | 32.01 |
|
| Tango Therapeutics (TNGX) | 1.5 | $30M | NEW | 1.4M | 20.92 |
|
| Pharvaris N V (PHVS) | 1.4 | $28M | -7% | 1.0M | 28.25 |
|
| Oruka Therapeutics (ORKA) | 1.3 | $26M | 533k | 49.05 |
|
|
| Agomab Therapeutics Nv Sponsored Ads | 1.3 | $26M | NEW | 2.5M | 10.49 |
|
| Maze Therapeatics (MAZE) | 1.1 | $22M | NEW | 750k | 29.85 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $22M | 2.3M | 9.39 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.1 | $22M | -5% | 95k | 228.73 |
|
| Roivant Sciences SHS (ROIV) | 1.0 | $21M | NEW | 750k | 27.70 |
|
| Adlai Nortye Sponsored Ads (ANL) | 1.0 | $20M | NEW | 2.9M | 6.92 |
|
| Terns Pharmaceuticals (TERN) | 0.8 | $16M | NEW | 300k | 52.72 |
|
| Tarsus Pharmaceuticals (TARS) | 0.8 | $16M | -10% | 225k | 70.15 |
|
| Biohaven (BHVN) | 0.7 | $15M | +17500% | 1.8M | 8.46 |
|
| Cabaletta Bio (CABA) | 0.7 | $15M | +25% | 5.5M | 2.69 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs | 0.7 | $13M | NEW | 1.3M | 10.16 |
|
| Arcutis Biotherapeutics (ARQT) | 0.5 | $11M | -10% | 450k | 23.56 |
|
| Sensei Biotherapeutics Com New (SNSE) | 0.5 | $9.7M | NEW | 306k | 31.52 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.5 | $9.1M | -16% | 250k | 36.32 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.4 | $8.6M | NEW | 1.5M | 5.95 |
|
| Axsome Therapeutics (AXSM) | 0.4 | $8.5M | -33% | 50k | 169.02 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $8.4M | NEW | 175k | 48.20 |
|
| Cogent Biosciences (COGT) | 0.4 | $7.7M | -11% | 200k | 38.49 |
|
| Monte Rosa Therapeutics (GLUE) | 0.3 | $6.6M | NEW | 400k | 16.45 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.3 | $6.3M | NEW | 100k | 62.70 |
|
| Vaxcyte (PCVX) | 0.3 | $5.8M | -20% | 100k | 58.11 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.2 | $4.9M | -12% | 350k | 13.90 |
|
| Rallybio Corp (RLYB) | 0.2 | $3.6M | NEW | 400k | 8.97 |
|
| Context Therapeutics (CNTX) | 0.1 | $1.4M | NEW | 530k | 2.62 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2026 Q1 filed May 15, 2026
- Cormorant Asset Management 2025 Q4 filed Feb. 17, 2026
- Cormorant Asset Management 2025 Q3 filed Nov. 14, 2025
- Cormorant Asset Management 2025 Q2 filed Aug. 14, 2025
- Cormorant Asset Management 2025 Q1 filed May 15, 2025
- Cormorant Asset Management 2024 Q4 filed Feb. 14, 2025
- Cormorant Asset Management 2024 Q3 filed Nov. 14, 2024
- Cormorant Asset Management 2024 Q2 filed Aug. 14, 2024
- Cormorant Asset Management 2024 Q1 filed May 15, 2024
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022
- Cormorant Asset Management 2022 Q2 filed Aug. 15, 2022